JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
AU2007287428B2
(en)
|
2006-08-24 |
2011-08-11 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
|
CL2007003520A1
(es)
|
2006-12-07 |
2008-08-22 |
Piramed Ltd Genentech Inc |
Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
|
ATE551334T1
(de)
*
|
2007-02-06 |
2012-04-15 |
Novartis Ag |
Pi3-kinase-hemmer und verfahren zu ihrer verwendung
|
JP5676249B2
(ja)
*
|
2007-04-20 |
2015-02-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
|
EP2155689B1
(en)
|
2007-05-31 |
2015-07-08 |
Boehringer Ingelheim International GmbH |
Ccr2 receptor antagonists and uses thereof
|
WO2009007750A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
|
WO2009017838A2
(en)
*
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
EP2211615A4
(en)
*
|
2007-10-22 |
2010-10-13 |
Glaxosmithkline Llc |
PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
|
WO2009066084A1
(en)
*
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
WO2009093981A1
(en)
*
|
2008-01-23 |
2009-07-30 |
S Bio Pte Ltd |
Triazine compounds as kinase inhibitors
|
KR20100131446A
(ko)
*
|
2008-03-05 |
2010-12-15 |
노파르티스 아게 |
Egfr 의존성 질환 또는 egfr 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도
|
AU2012203914C1
(en)
*
|
2008-03-26 |
2013-11-28 |
Novartis Ag |
5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes
|
CA2717948C
(en)
|
2008-03-26 |
2016-09-06 |
Novartis Ag |
5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
|
US20110053907A1
(en)
*
|
2008-03-27 |
2011-03-03 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
KR101956261B1
(ko)
|
2008-05-21 |
2019-03-08 |
어리어드 파마슈티칼스, 인코포레이티드 |
키나아제 억제제로서 포스포러스 유도체
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US20110105500A1
(en)
*
|
2008-06-27 |
2011-05-05 |
S*Bio Pte Ltd. |
Pyrazine substituted purines
|
WO2010006225A1
(en)
*
|
2008-07-11 |
2010-01-14 |
Novartis Ag |
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
|
KR20110041536A
(ko)
*
|
2008-07-29 |
2011-04-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
5-알키닐-피리미딘
|
US20100068204A1
(en)
*
|
2008-09-12 |
2010-03-18 |
Wyeth |
4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents
|
MX340304B
(es)
*
|
2008-10-01 |
2016-07-05 |
Novartis Ag * |
Antagonismo de smoothened para el tratamiento de los trastornos relacionados con la senda de hedgehog.
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
JP2012506898A
(ja)
*
|
2008-10-31 |
2012-03-22 |
ノバルティス アーゲー |
ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤とmTOR阻害剤との併用剤
|
JP5689069B2
(ja)
*
|
2008-11-20 |
2015-03-25 |
ジェネンテック, インコーポレイテッド |
ピラゾロピリジンpi3k阻害剤化合物及び使用方法
|
PL2379525T3
(pl)
|
2008-12-19 |
2016-01-29 |
Centrexion Therapeutics Corp |
Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
|
ES2617191T3
(es)
|
2009-03-05 |
2017-06-15 |
Daiichi Sankyo Company, Limited |
Derivado de piridina como inhibidor de PPARY
|
KR20110136880A
(ko)
|
2009-03-27 |
2011-12-21 |
패스웨이 테라퓨틱스 인코포레이티드 |
피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸 설폰아미드 및 암 치료법에서의 이의 용도
|
BRPI1015940A2
(pt)
*
|
2009-04-09 |
2016-04-19 |
Oncothyreon Inc |
métodos e composições de inibidores de pi-3 quinase para tratar fibrose
|
UY32582A
(es)
|
2009-04-28 |
2010-11-30 |
Amgen Inc |
Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
|
MX2011012201A
(es)
*
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
|
AU2010254161A1
(en)
*
|
2009-05-27 |
2011-11-10 |
F. Hoffmann-La Roche Ag |
Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use
|
ES2706185T3
(es)
|
2009-07-07 |
2019-03-27 |
Mei Pharma Inc |
Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer
|
US20120065166A1
(en)
*
|
2009-08-12 |
2012-03-15 |
Virginia Espina |
Bone Modulators And Methods Therewith
|
CN101993416B
(zh)
*
|
2009-08-27 |
2013-09-11 |
中国科学院上海药物研究所 |
喹啉类化合物、其制备方法、包含该化合物的药物组合物及该化合物的用途
|
TW201609747A
(zh)
*
|
2009-09-09 |
2016-03-16 |
阿維拉製藥公司 |
Pi3激酶抑制劑及其用途
|
EP2488532B1
(en)
|
2009-10-16 |
2018-05-09 |
Melinta Therapeutics, Inc. |
Antimicrobial compounds and methods of making and using the same
|
MY176900A
(en)
|
2009-10-16 |
2020-08-26 |
Rib X Pharmaceuticals Inc |
Antimicrobial compounds and methods of making and using the same
|
RS53555B1
(en)
|
2009-12-17 |
2015-02-27 |
Boehringer Ingelheim International Gmbh |
NEW CCR2 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
EP2569295B1
(en)
|
2010-05-12 |
2014-11-19 |
Boehringer Ingelheim International GmbH |
New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
JP2013526507A
(ja)
|
2010-05-12 |
2013-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用
|
US8841313B2
(en)
|
2010-05-17 |
2014-09-23 |
Boehringer Ingelheim International Gmbh |
CCR2 antagonists and uses thereof
|
EP2576542B1
(en)
|
2010-05-25 |
2015-04-22 |
Boehringer Ingelheim International GmbH |
Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
|
WO2011151251A1
(en)
|
2010-06-01 |
2011-12-08 |
Boehringer Ingelheim International Gmbh |
New ccr2 antagonists
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
WO2012033091A1
(ja)
|
2010-09-07 |
2012-03-15 |
第一三共株式会社 |
安息香酸エステル類の製造法
|
CN103140479B
(zh)
|
2010-10-01 |
2015-04-08 |
诺华有限公司 |
制造嘧啶衍生物的方法
|
EP2627179A4
(en)
*
|
2010-10-14 |
2014-04-02 |
Ariad Pharma Inc |
METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS
|
JP2014503488A
(ja)
*
|
2010-11-12 |
2014-02-13 |
バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー |
プロパ−2−エン−1−アミンから出発して2,2−ジフルオロエチルアミンを調製する方法
|
MX2013005271A
(es)
*
|
2010-11-12 |
2013-09-26 |
Univ Texas |
Terapia de combinacion con dexametasona.
|
WO2012085815A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors
|
MX2013009256A
(es)
*
|
2011-02-11 |
2013-12-09 |
Dana Farber Cancer Inst Inc |
Metodo para inhibir las celulas tumorales hamartoma.
|
CZ305457B6
(cs)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
JP5999177B2
(ja)
|
2011-05-04 |
2016-09-28 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
EP2726074B1
(en)
*
|
2011-07-01 |
2018-04-04 |
Novartis AG |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
JP5786258B2
(ja)
|
2011-07-15 |
2015-09-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規かつ選択的なccr2拮抗薬
|
DK3409278T3
(da)
|
2011-07-21 |
2020-11-09 |
Sumitomo Dainippon Pharma Oncology Inc |
Heterocykliske proteinkinaseinhibitorer
|
BR112014004587A2
(pt)
|
2011-08-31 |
2017-03-14 |
Novartis Ag |
combinações sinérgicas de inibidores de pi3k- e de mek
|
BR112014004577A2
(pt)
*
|
2011-09-01 |
2017-04-04 |
Novartis Ag |
inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
|
CN103958506B
(zh)
|
2011-09-27 |
2017-02-22 |
诺华股份有限公司 |
用作突变idh抑制剂的3‑嘧啶‑4‑基‑噁唑烷‑2‑酮化合物
|
WO2013049581A1
(en)
*
|
2011-09-30 |
2013-04-04 |
Beth Israel Deaconess Medical Center Inc. |
Compositions and methods for the treatment of proliferative diseases
|
US20140288073A1
(en)
*
|
2011-10-28 |
2014-09-25 |
Novartis Ag |
Method of Treating Gastrointestinal Stromal Tumors
|
US20140343128A1
(en)
*
|
2011-11-15 |
2014-11-20 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP2841428B1
(en)
|
2012-04-24 |
2018-08-22 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
SG11201406550QA
(en)
*
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
US20170002313A1
(en)
|
2012-05-23 |
2017-01-05 |
Genentech Inc. |
Compositions and methods of obtaining and using endoderm and hepatocyte cells
|
RU2014154009A
(ru)
*
|
2012-06-06 |
2016-08-10 |
Новартис Аг |
Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
US9630958B2
(en)
*
|
2012-07-23 |
2017-04-25 |
Sphaera Pharma Pte. Ltd. |
Triazine compounds
|
EP2885003B1
(en)
*
|
2012-08-16 |
2021-09-29 |
Novartis AG |
Combination of pi3k inhibitor and c-met inhibitor
|
CN102952086B
(zh)
*
|
2012-09-28 |
2013-08-28 |
天津科创医药中间体技术生产力促进有限公司 |
一种2-吗啉基取代嘧啶类化合物的制备方法
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
WO2014064058A1
(en)
|
2012-10-23 |
2014-05-01 |
Novartis Ag |
Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
|
US9296733B2
(en)
*
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
KR20150084992A
(ko)
|
2012-11-16 |
2015-07-22 |
머크 샤프 앤드 돔 코포레이션 |
인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제
|
WO2014093230A2
(en)
*
|
2012-12-10 |
2014-06-19 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
WO2014090147A1
(zh)
*
|
2012-12-14 |
2014-06-19 |
上海恒瑞医药有限公司 |
嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
|
KR102313997B1
(ko)
|
2013-02-20 |
2021-10-20 |
노파르티스 아게 |
인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
|
GB201303109D0
(en)
*
|
2013-02-21 |
2013-04-10 |
Domainex Ltd |
Novel pyrimidine compounds
|
WO2014136048A1
(en)
*
|
2013-03-06 |
2014-09-12 |
Novartis Ag |
Formulations of organic compounds
|
DK3527563T3
(da)
|
2013-03-12 |
2021-12-06 |
Vertex Pharma |
Dna-pk-inhibitorer
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
PE20151939A1
(es)
|
2013-03-14 |
2016-01-08 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Jak2およびalk2阻害剤およびその使用方法
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
HUE055072T2
(hu)
|
2013-03-21 |
2021-10-28 |
Array Biopharma Inc |
B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
CA2907912A1
(en)
*
|
2013-05-01 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
C-linked heterocycloalkyl substituted pyrimidines and their uses
|
TWI622587B
(zh)
*
|
2013-05-01 |
2018-05-01 |
赫孚孟拉羅股份公司 |
二雜芳基化合物及其用途
|
PL2994126T3
(pl)
*
|
2013-05-07 |
2018-11-30 |
Novartis Ag |
Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi
|
CN105283180A
(zh)
|
2013-06-11 |
2016-01-27 |
诺华股份有限公司 |
Pi3k抑制剂与微管去稳定剂的药物组合
|
AU2014282798A1
(en)
|
2013-06-18 |
2015-12-03 |
Novartis Ag |
Pharmaceutical combinations
|
CN105611928A
(zh)
|
2013-08-08 |
2016-05-25 |
诺华股份有限公司 |
Pim激酶抑制剂组合
|
WO2015022609A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2015022657A1
(en)
|
2013-08-16 |
2015-02-19 |
Novartis Ag |
Pharmaceutical combinations
|
MX2016002975A
(es)
|
2013-09-09 |
2016-10-21 |
Melinta Therapeutics Inc |
Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
|
WO2015035421A1
(en)
|
2013-09-09 |
2015-03-12 |
Melinta Therapeutics, Inc. |
Antimicrobial compounds and methods of making and using the same
|
CN103483345B
(zh)
*
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
RU2675270C2
(ru)
|
2013-10-17 |
2018-12-18 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы и содержащие их фармацевтические композиции
|
MX2016009226A
(es)
*
|
2014-01-15 |
2016-10-05 |
Novartis Ag |
Combinaciones farmaceuticas.
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
MX2016011993A
(es)
|
2014-03-14 |
2016-12-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
|
JP6513105B2
(ja)
|
2014-04-22 |
2019-05-15 |
ウニヴェルズィテート バーゼル |
トリアジン、ピリミジン及びピリジン誘導体の新規製造方法
|
WO2016001789A1
(en)
*
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
WO2016023082A1
(en)
|
2014-08-12 |
2016-02-18 |
Monash University |
Lymph directing prodrugs
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
CN104151256B
(zh)
*
|
2014-08-14 |
2016-08-24 |
西安交通大学 |
二取代苯甲酰胺类化合物及其合成方法和应用
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
CN105461714B
(zh)
*
|
2014-09-29 |
2017-11-28 |
山东轩竹医药科技有限公司 |
并环类pi3k抑制剂
|
CN107106687A
(zh)
|
2014-10-03 |
2017-08-29 |
诺华股份有限公司 |
组合治疗
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
MA40933A
(fr)
|
2014-11-11 |
2017-09-19 |
Piqur Therapeutics Ag |
Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
|
MX2017006301A
(es)
|
2014-11-14 |
2017-08-21 |
Novartis Ag |
Conjugados de anticuerpo- farmaco.
|
CN105085476B
(zh)
*
|
2014-11-24 |
2018-03-09 |
苏州晶云药物科技有限公司 |
5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
|
ES2784900T3
(es)
*
|
2014-12-12 |
2020-10-01 |
Massachusetts Gen Hospital |
Tratamiento de metástasis cerebrales del cáncer de mama
|
WO2016095833A1
(zh)
*
|
2014-12-17 |
2016-06-23 |
上海海雁医药科技有限公司 |
2-吗啉-4,6-二取代的嘧啶衍生物、其制法与医药上的用途
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
CR20170285A
(es)
|
2014-12-23 |
2017-08-21 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos
|
CN105832741A
(zh)
*
|
2015-01-16 |
2016-08-10 |
复旦大学 |
Pi3k抑制剂与紫杉醇的药物组合物及其在制备抗肿瘤药物中的应用
|
CN107530304A
(zh)
|
2015-02-27 |
2018-01-02 |
科泰纳制药公司 |
Olig2活性的抑制
|
US20160251376A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
BR112017018908A2
(pt)
|
2015-03-10 |
2018-04-17 |
Aduro Biotech, Inc. |
composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
|
MX2017011616A
(es)
|
2015-03-11 |
2018-04-11 |
Melinta Therapeutics Inc |
Compuestos antimicrobianos y métodos para hacerlos y usarlos.
|
US9481665B2
(en)
*
|
2015-03-13 |
2016-11-01 |
Yong Xu |
Process for preparing PI3K inhibitor buparsilib
|
US10130629B2
(en)
|
2015-03-25 |
2018-11-20 |
Novartis Ag |
Pharmaceutical combinations
|
BR112017016817A2
(pt)
|
2015-03-25 |
2018-04-03 |
Novartis Ag |
derivados heterocíclicos formilados como inibidores de fgfr4
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
BR112017028492B1
(pt)
|
2015-07-02 |
2023-12-26 |
Centrexion Therapeutics Corporation |
Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3340989B1
(en)
|
2015-08-28 |
2023-08-16 |
Novartis AG |
Mdm2 inhibitors and combinations thereof
|
CN105001151B
(zh)
*
|
2015-08-28 |
2017-07-14 |
苏州明锐医药科技有限公司 |
布帕尼西中间体及其制备方法
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
JP7118888B2
(ja)
|
2015-09-08 |
2022-08-16 |
モナッシュ ユニバーシティ |
リンパ指向性プロドラッグ
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
EP4112611A3
(en)
|
2015-10-23 |
2023-03-22 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
WO2017077445A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
BR112018008904A2
(pt)
|
2015-11-03 |
2018-11-27 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a tim-3 e seus usos
|
MX2018006777A
(es)
|
2015-12-03 |
2018-08-01 |
Novartis Ag |
Tratamiento de cancer con un inhibidor de pi3k en un paciente previamente seleccionado por tener una mutacion de pik3ca en el ctadn.
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
CN106883185B
(zh)
*
|
2015-12-15 |
2021-07-09 |
重庆博腾制药科技股份有限公司 |
一种4-氯-2-三氟甲基嘧啶的制备方法
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
PL3426243T3
(pl)
|
2016-03-09 |
2021-10-04 |
Raze Therapeutics, Inc. |
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
EP3231799A1
(en)
*
|
2016-04-14 |
2017-10-18 |
Universität Basel |
4-(azetidin-1-yl)pyrimidine derivatives with anti-mitotic and anti-proliferative activity
|
RU2018140001A
(ru)
|
2016-05-18 |
2020-06-18 |
Пикур Терапьютикс Аг |
Лечение повреждений кожи
|
CN109475560B
(zh)
*
|
2016-05-18 |
2023-05-02 |
巴塞尔大学 |
神经病症的治疗
|
US10544137B2
(en)
|
2016-06-02 |
2020-01-28 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
|
EP3472161B1
(en)
|
2016-06-20 |
2020-03-25 |
Novartis AG |
Triazolopyridine compounds and uses thereof
|
BR112018076443A2
(pt)
|
2016-06-20 |
2019-04-09 |
Novartis Ag |
formas cristalinas de um composto de triazolopirimidina
|
JP2019524872A
(ja)
|
2016-06-20 |
2019-09-05 |
ノバルティス アーゲー |
癌の治療に有用なイミダゾピリミジン化合物
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
CN116554168A
(zh)
|
2016-06-21 |
2023-08-08 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
CN106905294A
(zh)
*
|
2016-07-08 |
2017-06-30 |
苏州科睿思制药有限公司 |
5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
|
CA3038657A1
(en)
|
2016-09-27 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
|
JP2019536471A
(ja)
|
2016-09-27 |
2019-12-19 |
セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. |
キメラエンガルフメント受容体分子
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
CN110603261A
(zh)
|
2016-12-23 |
2019-12-20 |
拜斯科阿迪有限公司 |
具有新型键结构的肽衍生物
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
GB201705263D0
(en)
*
|
2017-03-31 |
2017-05-17 |
Probiodrug Ag |
Novel inhibitors
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
CN116370448A
(zh)
|
2017-04-26 |
2023-07-04 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
EP3630118A4
(en)
|
2017-05-23 |
2021-03-31 |
MEI Pharma, Inc. |
POLYTHERAPY
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
EA201992765A1
(ru)
|
2017-05-24 |
2020-03-25 |
Новартис Аг |
Белки на основе антител с привитым цитокином и способы их применения в лечении рака
|
AU2018290237A1
(en)
|
2017-06-22 |
2020-01-16 |
Novartis Ag |
Antibody molecules to CD73 and uses thereof
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
MA49921A
(fr)
|
2017-08-14 |
2021-05-12 |
Mei Pharma Inc |
Polythérapie
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
US10800774B2
(en)
*
|
2017-08-17 |
2020-10-13 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of ATR kinase
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
US11708423B2
(en)
|
2017-09-26 |
2023-07-25 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
CN109651341A
(zh)
*
|
2017-10-11 |
2019-04-19 |
上海医药工业研究院 |
二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用
|
EP3694511A1
(en)
|
2017-10-13 |
2020-08-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment of pancreatic cancer
|
EP3713963A1
(en)
|
2017-11-23 |
2020-09-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new marker for predicting the sensitivity to pi3k inhibitors
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
MX2020006613A
(es)
|
2017-12-22 |
2020-11-13 |
Ravenna Pharmaceuticals Inc |
Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
|
CA3085366A1
(en)
|
2017-12-22 |
2019-06-27 |
Petra Pharma Corporation |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
AU2018396142A1
(en)
|
2017-12-26 |
2020-07-16 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Gcn2阻害剤およびその使用
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
KR20200140262A
(ko)
|
2018-02-27 |
2020-12-15 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
CN112218886A
(zh)
|
2018-03-28 |
2021-01-12 |
森罗治疗公司 |
嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途
|
US20210087251A1
(en)
|
2018-03-28 |
2021-03-25 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2019191340A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
MX2020010437A
(es)
|
2018-04-05 |
2021-01-29 |
Sumitomo Pharma Oncology Inc |
Inhibidores de axl cinasa y uso de los mismos.
|
BR112020019732A2
(pt)
*
|
2018-04-06 |
2021-02-17 |
Nippon Soda Co., Ltd. |
composto, formulações para controlar organismos nocivos e para controlar ou exterminar endoparasitas, e, formulações inseticida ou acaricida e nematicida.
|
EP3774792B1
(en)
*
|
2018-04-10 |
2022-09-14 |
Neuropore Therapies, Inc. |
Morpholine derivates as inhibitors of vps34
|
CN112189012B
(zh)
*
|
2018-04-10 |
2024-02-13 |
神经孔疗法股份有限公司 |
作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
|
WO2019209759A1
(en)
|
2018-04-24 |
2019-10-31 |
Merck Patent Gmbh |
Antiproliferation compounds and uses thereof
|
US11059826B2
(en)
|
2018-04-24 |
2021-07-13 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20210021534A
(ko)
|
2018-06-15 |
2021-02-26 |
나비토르 파마슈티칼스 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
CN108864067B
(zh)
*
|
2018-06-20 |
2020-05-12 |
郑州大学 |
一种2-炔丙巯基-5-氰基嘧啶类衍生物及其制备方法和应用
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
EP3826684A4
(en)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF
|
JP7328323B2
(ja)
|
2018-08-17 |
2023-08-16 |
ノバルティス アーゲー |
SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
CN113164419A
(zh)
|
2018-09-07 |
2021-07-23 |
皮克医疗公司 |
Eif4e抑制剂和其用途
|
AU2019360941A1
(en)
|
2018-10-15 |
2021-04-29 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
POLYMORPHIC COMPOUNDS AND USES THEREOF
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
JP2022516401A
(ja)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
CN113271938A
(zh)
|
2018-11-30 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3123996A1
(en)
|
2018-12-21 |
2019-12-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
CN109651297B
(zh)
*
|
2019-01-22 |
2022-05-27 |
杭州壹瑞医药科技有限公司 |
一种n-苄基-n-芳基磺酰胺类衍生物及制备和应用
|
CN109705033B
(zh)
*
|
2019-01-22 |
2021-03-30 |
杭州壹瑞医药科技有限公司 |
N-杂芳基磺酰胺类衍生物及制备和应用
|
AU2020212001A1
(en)
|
2019-01-23 |
2021-07-22 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US11471456B2
(en)
|
2019-02-12 |
2022-10-18 |
Sumitomo Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
WO2020201753A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(zh)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
WO2021001431A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
|
WO2021001426A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ultrafast elasticity imaging for detecting pancreatic cancers
|
WO2021001427A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
|
MX2022000164A
(es)
|
2019-07-03 |
2022-04-01 |
Sumitomo Pharma Oncology Inc |
Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
|
CN115038688A
(zh)
|
2019-09-11 |
2022-09-09 |
文森雷生物科学股份有限公司 |
Usp30抑制剂及其用途
|
WO2021050964A1
(en)
|
2019-09-13 |
2021-03-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
EP4051259A4
(en)
|
2019-11-01 |
2023-11-22 |
Navitor Pharmaceuticals, Inc. |
TREATMENT METHODS USING AN MTORC1 MODULATOR
|
US11819476B2
(en)
|
2019-12-05 |
2023-11-21 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
MX2022007841A
(es)
|
2019-12-23 |
2022-07-19 |
Kymera Therapeutics Inc |
Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
|
CN115151534B
(zh)
*
|
2020-02-14 |
2024-02-06 |
南京药石科技股份有限公司 |
白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
CA3171258A1
(en)
|
2020-03-19 |
2021-09-23 |
Nan JI |
Mdm2 degraders and uses thereof
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
KR20210158019A
(ko)
|
2020-06-23 |
2021-12-30 |
주식회사 온코빅스 |
포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
TW202227089A
(zh)
|
2020-11-30 |
2022-07-16 |
大陸商杭州阿諾生物醫藥科技有限公司 |
用於治療pik3ca突變癌症的組合療法
|
CN117015531A
(zh)
|
2020-12-02 |
2023-11-07 |
医肯纳肿瘤学公司 |
Tead抑制剂及其用途
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
WO2022167445A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
WO2022167457A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
CN117203223A
(zh)
|
2021-02-26 |
2023-12-08 |
凯洛尼亚疗法有限公司 |
淋巴细胞靶向慢病毒载体
|
EP4301756A1
(en)
|
2021-03-05 |
2024-01-10 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
CN117157284A
(zh)
*
|
2021-03-18 |
2023-12-01 |
苏州国匡医药科技有限公司 |
Ctla-4小分子降解剂及其应用
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
WO2023107603A1
(en)
*
|
2021-12-08 |
2023-06-15 |
Kineta, Inc. |
Pyrimidines and methods of their use
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
CN114213340B
(zh)
|
2022-02-22 |
2022-06-07 |
北京蓝晶微生物科技有限公司 |
2,4-二氨基嘧啶氧化物的制备方法
|
CN114591326B
(zh)
*
|
2022-02-28 |
2024-02-27 |
上海筛杰生物医药有限公司 |
Cct-251921的中间体及其制备方法
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|